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Abstract
 
Immunization with vaccinia virus resulted in long-lasting protection against smallpox and was
the approach used to eliminate natural smallpox infections worldwide. Due to the concern
about the potential use of smallpox virus as a bioweapon, smallpox vaccination is currently be-
ing reintroduced. Severe complications from vaccination were associated with congenital or
acquired T cell deficiencies, but not with congenital agammaglobulinemia, suggesting the im-
portance of T cell immunity in recovery from infection. In this report, we identified two
CD8
 
 
 
 T cell epitopes restricted by the most common human major histocompatibility com-
plex (MHC) class I allele, HLA-A
 
*
 
0201. Both epitopes are highly conserved in vaccinia and
variola viruses. The frequency of vaccinia-specific CD8
 
 
 
 T cell responses to these epitopes
measured by interferon (IFN)-
 
 
 
 enzyme-linked immunospot (ELISPOT) assay and HLA/pep-
tide tetramer staining peaked 2 wk after primary immunization and then declined, but were
still detectable 1 to 3 yr after primary immunization. 2 wk after immunization, IFN-
 
 
 
–produc-
ing cells specific to these two epitopes were 14% of total vaccinia virus-specific IFN-
 
 
 
–produc-
ing cells in one donor, 35% in the second donor, and 6% in the third donor. This information
will be useful for studies of human T cell memory and for the design and analyses of the immu-
nogenicity of experimental vaccinia vaccines.
Key words: immunologic memory • T lymphocyte epitopes • cytotoxic T lymphocytes • 
smallpox vaccine • major histocompatibility complex
 
Introduction
 
Immunization with vaccinia virus resulted in long-lasting
protection against smallpox and was the successful approach
used to eliminate natural smallpox infections worldwide.
This accomplishment was achieved without a detailed un-
derstanding of human T cell responses to poxviruses. Severe
and life threatening complications from vaccination were as-
sociated with congenital or acquired T cell deficiencies, but
not with congenital agammaglobulinemia (1). In addition to
emphasizing the importance of T cells in the immunity to
smallpox, this finding suggests a critical need to develop new
vaccines safe for use in T cell–deficient populations.
Due to the concern about the potential use of smallpox
virus as a bioweapon, smallpox vaccination is currently be-
ing reintroduced. Considering the high incidence of side
effects from current smallpox vaccine, the development of
a safer, but equally effective vaccine is very important (2).
To analyze T cell responses to licensed and experimental
smallpox vaccines at the single cell level, it is essential to
identify CD8
 
 
 
 T cell epitopes. We detected vaccinia-spe-
cific CD4
 
 
 
 and CD8
 
 
 
 T cells in humans and have mea-
sured the number of vaccinia virus-specific T cell responses
to smallpox vaccine (3–7). An intracellular cytokine stain-
ing assay was applied to quantitate and characterize vac-
cinia-specific T cells in mice (8). However, no T cell
epitopes have been identified in humans or mice systems.
One major obstacle is the size of the virus. Vaccinia is a
large virus with an 
 
 
 
200-kbp DNA genome that has 
 
 
 
200
open reading frames (9).
Among the highly polymorphic human MHC class I
genes we chose HLA-A
 
*
 
0201 to identify CD8
 
 
 
 T cell
epitopes because of the commonality of this allele among
most ethnic groups (10). We first established several vac-
cinia-specific HLA-A
 
*
 
0201–restricted CTL lines, and then
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identified CD8
 
 
 
 T cell epitopes recognized by these CTL
lines in cytotoxicity assays using synthetic vaccinia peptides
designed based on the HLA-A
 
*
 
0201 binding motif (11).
In this report we identified two CD8
 
 
 
 T cell epitopes
that are highly-conserved between vaccinia and variola
(smallpox) viruses. The induction of the T cell responses
after primary smallpox vaccination is demonstrated by the
kinetics of epitope specific CD8
 
 
 
 T cells in three HLA-
A
 
*
 
0201–positive individuals. This information will be use-
ful for the design and analyses of the immunogenicity of
experimental vaccinia vaccines, and for basic studies of hu-
man T cell memory.
 
Materials and Methods
 
Donors.
 
Donors in this study were three HLA-A
 
*
 
0201–posi-
tive laboratory workers received primary immunization by scari-
fication with the licensed smallpox vaccine, Dryvax
 
®
 
, as recom-
mended by the Centers for Disease Control and Prevention for
laboratory personnel working with vaccinia viruses. The HLA-A
and B alleles of donor 1 were A2 (A
 
*
 
0201), B15, B18; those of
donor 2 were A2 (A
 
*
 
0201), B15, B44; and those of donor 3 were
A2 (A
 
*
 
0201), A31, B40, B51.
 
Viruses.
 
Vaccinia virus New York City Board of Health
(NYCBH), the same strain used to produce Dryvax
 
®
 
, was pro-
vided by Gail Mazzara and Dennis Panicali of Applied Biotech-
nology, Inc., and propagated and titrated in CV-1 cells (Ameri-
can Type Culture Collection no. CCL-70) as previously
described (3, 12). Modified vaccinia virus Ankara strain (MVA)
was supplied by Bernard Moss of National Institute of Allergy
and Infectious Diseases/National Institutes of Health (Bethesda,
MD), and was propagated and titrated in BHK-21 cells (Ameri-
can Type Culture Collection no. CCL-10) following published
methods (13).
 
CTL Lines.
 
Vaccinia virus-specific CTL lines were isolated
from PBMCs of immunized donors by limiting dilution cloning
(4). Vaccinia virus NYCBH strain was used to stimulate PBMCs
for cloning and to infect target cells for cytotoxicity assays. Cyto-
toxicity assays were performed as previously described (7). Hmy
C1R A2.1 cells (gift from William E. Biddison of NIH/NINDS),
which express only HLA-A
 
*
 
0201 at normal levels, were used as
targets in cytotoxicity assay to confirm the HLA-A
 
*
 
0201 restric-
tion. Surface expression of CD4 and CD8 was determined by
flow cytometry using FITC-conjugated antibodies (Becton Dick-
inson). Cross-reactivity of CTL lines was determined using autol-
ogous B-LCLs (B-lymphoblastoid cell lines), that were infected
with MVA as target cells in cytotoxicity assays.
 
Screening Peptides in Cytotoxicity Assay.
 
Peptides were synthe-
sized with a Symphony automated peptide synthesizer at the Pro-
tein Core Facility in the University of Massachusetts Medical
School or purchased from Mimotopes Pty. Ltd. When predicted
epitopes overlapped, we made them as a longer peptide fragment.
For technical reasons some of these screening peptides were made
as a 13 mer instead of a 9 mer. In screening cytotoxicity assays,
mixtures of five peptides were used and the concentration of each
peptide was 5 
 
 
 
g/ml. When the peptide recognized was longer
than 9 amino acids, truncated 9 mer peptide epitopes were con-
structed and analyzed in cytotoxicity assays. All peptides recog-
nized were tested in dose–response experiments (Fig. 1).
 
Tetramer Staining.
 
Peptide/HLA-A
 
*
 
0201 tetramers were made
in the Tetramer Core Facility in the University of Massachusetts
Medical School following the protocol published previously (14).
Each lot of tetramer was titrated using CTL lines specific to the
peptide mixed with autologous PBMCs at a 1 to 10 (or 20) ratio
to determine the optimal concentration for staining.
 
IFN-
 
 
 
 ELISPOT Assay.
 
IFN-
 
 
 
 ELISPOT assays were per-
formed as described previously (6). For stimulation, PBMCs were
incubated with vaccinia virus NYCBH strain at an MOI of 1 or
with peptide at a final concentration of 10 
 
 
 
g/ml for 16 h.
 
Results
 
Vaccinia virus-specific CD8
 
 
 
 CTL lines were established
by limiting dilution cloning from the PBMCs of HLA-
A
 
*
 
0201–positive donors who received primary immuniza-
tion with the licensed smallpox vaccine, Dryvax
 
®
 
. We de-
cided to identify T cell epitopes restricted by HLA-A
 
*
 
0201
and cross-reactive to MVA, which is being proposed for
use as an attenuated smallpox vaccine and as a vector for
vaccination against other infectious agents (15). We per-
formed HLA-A
 
*
 
0201 peptide binding motif searches on all
of the protein sequences of the MVA strain (16). We used
the computer algorithm “HLA Peptide Binding Pre-
dictions” (http://bimas.dcrt.nih.gov/molbio/hla_bind/) to
calculate the binding affinity (score) of 9 mer peptides to
the HLA-A
 
*
 
0201 molecule (11). We hypothesized that
early gene products may be more likely to have CD8
 
 
 
 T
cell epitopes. In both humans and mice all of the known
CD8
 
 
 
 T cell epitopes to cytomegalovirus are encoded by
immediate-early phase proteins (17, 18). The early, early
and late, and late genes in vaccinia were categorized by nu-
cleotide sequence motifs, such as a late promoter or an
early termination motif (19). For initial screening we syn-
thesized all peptides with; (a) a binding score of more than
a 1,000 (70 peptides); or (b) a binding score of 100 to 999
and encoded by a gene expressed early or both early and
late (125 peptides). A total of 195 peptides were screened
using the fifteen CTL lines.
One CTL line, VA55 3.13, established from donor 2,
recognized a peptide 74A, CLTEYILWV, in a 21.7K pro-
tein encoded by a putative early and late gene, “189R,” of
the MVA strain with a calculated binding score of 3607.
Another CTL line, VA49 3.12, established from donor 1,
recognized a peptide 165, KVDDTFYYV, which is in a
host range protein encoded by a putative early and late
gene, “018L,” with a calculated binding score of 365. Fig. 1
demonstrates the high level of specific recognition by these
CTL lines of their respective epitope peptides in a dose
response CTL experiment. These epitope sequences are
highly-conserved in vaccinia and variola viruses (Table I).
CD8
 
 
 
 T cells specific to these epitopes were measured at
several time points after primary immunization by peptide/
HLA-A
 
*
 
0201 tetramer staining using the PBMCs of three
HLA-A
 
*
 
0201–positive donors. Fig. 2 shows representative
FACS
 
®
 
 plots of donor 1 PBMC. In Figs. 3 and 4, “preim-
mune” means before primary first immunization, and “two
weeks” means two weeks after the second immunization
for donor 3 who failed to develop a “take” after primary
immunization, and twenty days after primary immuniza-T
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tion was immunized for the second time. In all three do-
nors the frequency of vaccinia-specific CD8
 
 
 
 T cells
peaked 2 wk after primary immunization and then de-
clined, but were still detectable 1 to 3 yr after primary im-
munization (Fig. 3). 2 wk after vaccination the IFN-
 
 
 
–pro-
ducing cells specific to these two epitopes were 14% of
total vaccinia virus-specific IFN-
 
 
 
–producing cells in do-
nor 1, 35% in donor 2, and 6% in donor 3 (Fig. 4).
 
Discussion
 
In this report we identified two CD8
 
 
 
 T cell epitopes re-
stricted by HLA-A
 
*
 
0201, the most common MHC class I
allele in humans. These are the first T cell epitopes that
have been reported for vaccinia virus. IFN-
 
 
 
–producing
cells specific to these two epitopes represented 6 to 35% of
total number of IFN-
 
 
 
–producing cells specific to vaccinia
virus. The frequency of epitope-specific T cells was always
higher by peptide/HLA tetramer staining than by IFN-
 
 
 
–
ELISPOT assay, although post-vaccination kinetics for each
epitope-specific T cell were similar using both methods.
As for epitope selection, peptide 74A was the 15th high-
est binding peptide to HLA-A
 
*
 
0201 of the 195 peptides
we selected for screening and peptide 165 was the 95th
highest binder. We did not experimentally measure bind-
ing affinity of these peptides, but they are not epitopes
based solely on their HLA-A
 
*
 
0201 binding affinity. One
common characteristic of these two peptides is that they
are both encoded by genes with a late promoter and an
early termination motif (19), which means they may be
expressed at both early and late phases of infection. The
189R gene of MVA strain encoding peptide 74A is a non-
essential gene (20) with unknown function (21). The 018L
gene of MVA encoding peptide 165 is an ortholog of the
host range protein, C7L, of the Copenhagen strain (22).
Although our selection of peptides was biased toward
 
Table I.
 
Conservation of Epitopes Among Poxviruses Causing Infection in Human
 
GenBank/EMBL/DDBJ
accession no. Gene name 74A peptide Gene name 165 peptide
Vaccinia
MVA U94848 189R
 
CLTEYILWV
 
018L
 
KVDDTFYYV
 
Copenhagen M35027 B22R & C16L
 
b
 
*********
 
C7L
 
*********
 
Tian Tan
 
a
 
AF095689 TC7L
 
*********
 
Variola major
Bangladesh-1975 L22579 D2L
 
*********
 
D11L
 
*********
 
India-1967 X69198 D1L
 
*********
 
D8L
 
*********
 
Variola minor
Garcia-1966 Y16780 B1L
 
*********
 
B14L
 
*********
 
Cowpox
Brighton Red AF482758 V212
 
*********
 
V028
 
*********
 
Monkeypox
Zaire-96-I-16 AF380138 N1R
 
*********
 
D10L
 
***
 
Y
 
*
 
L
 
***
 
Only strains of which complete genome has been sequenced are listed. 
 
*
 
 indicate identical amino acid.
 
a
 
Tian Tan strain does not have 189R ortholog according to the nucleotide sequence.
 
b
 
Both genes are located within the inverted terminal repeats and the gene sequences are identical. 
Figure 1. Recognition of peptides 74A and 165 by cy-
totoxic T cell lines. CTL lines, VA55 3.13 (for 74A pep-
tide) and VA49 3.12 (for 165 peptide), were tested against
Hmy C1R-A2.1 cells pulsed with peptides at the indicated
concentrations. Effector/target ratio was 5.T
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Figure 2. Quantitation of
vaccinia virus epitope-specific
CD8  T cells by HLA-A*0201/
peptide 74A tetramer staining
(top) and HLA-A*0201/peptide
165 tetramer staining (bottom)
of PBMCs of donor 1. Cells
were gated on CD3  and CD4 
cells with tetramer staining on
the x-axis and CD8 on the
y-axis. The larger squares show
CD8  cells and the smaller
squares show CD8  and
tetramer  cells.
Figure 3. Kinetics of the fre-
quency of CD8  T cells specific
for each epitope quantitated by
tetramer staining in PBMCs of
three donors after primary im-
munization. Closed circle, 74A-
specific; open circle, 165-specific;
P, preimmunization. Frequency
is calculated per million PBMCs
for comparison with the data from
epitope-specific IFN-  ELISPOT
assays.
Figure 4. Kinetics of the fre-
quency of IFN- –producing cells
specific to these peptides and to
whole vaccinia virus quantitated
by IFN-  ELISPOT assay using
the PBMCs of the same donors
shown in Fig. 3. Closed circle,
peptide 74A–specific cells; open
circle, peptide 165–specific cells;
closed square, vaccinia virus–
specific cells; P, preimmunization.
Frequency is calculated per mil-
lion PBMC.T
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genes expressed in the early phase of infection, viral pro-
teins produced in the early phase of infection may be pro-
cessed and presented more efficiently by infected cells than
those produced only in late phase, as a result of vaccinia vi-
rus down-regulating host protein synthesis. These two
epitopes are highly conserved among variola viruses, sug-
gesting the CTLs recognizing these epitopes will recognize
variola virus-infected cells.
The frequency of epitope-specific HLA-A
 
*
 
0201–
restricted T cells varied among the three donors. Boon et al.
reported that the HLA class I background of individuals has
a major influence on the magnitude and specificity of the
CTL response against influenza A virus. Even in individuals
who share a certain HLA allele, the CTL response re-
stricted by that HLA allele differs and may be affected by
other nonmatching HLA molecules resulting in different
CTL responses (23). To determine immunodominance we
need to identify other CD8
 
 
 
 T cell epitopes, and analyze
the PBMCs of more donors with different combinations of
MHC class I molecules (24).
After submission of this paper for publication, Drexler et
al. published a report of a vaccinia virus epitope that they
found in HLA-A
 
*
 
0201-transgenic mice (25). Their epitope
is different from the two we report in this publication.
They did not report any experiments with quantitation of
human T cells specific to their epitope. We failed to detect
responses to that epitope by IFN-
 
 –ELISPOT assay in the
three vaccinated individuals who developed responses to
the two epitopes we now report. We conclude that the
epitopes reported here are dominant to the one reported
recently by Drexler et al.
Identification of these epitopes will enable the analysis
and quantitation of vaccinia virus-specific CD8  T cells in
the acute and memory phases and to compare CD8  T cell
responses specific to different epitopes. We should also be
able to monitor expansion and subsequent shrinkage of
epitope-specific CD8  T cells at the T cell receptor level.
Definition of T cell epitopes will help us to better under-
stand human T cell responses to vaccinia virus as a model of
human infection. In addition, it will provide a quantitative
measure of poxvirus T cell immunity when these viruses
are used as viral vectors.
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